ABIOMED (ABMD) : Sectoral Asset Management Inc scooped up 244,738 additional shares in ABIOMED during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 12, 2016. The investment management firm now holds a total of 298,338 shares of ABIOMED which is valued at $36,901,427.ABIOMED makes up approximately 3.49% of Sectoral Asset Management Inc’s portfolio.
Other Hedge Funds, Including , Vident Investment Advisory reduced its stake in ABMD by selling 18,464 shares or 74.03% in the most recent quarter. The Hedge Fund company now holds 6,476 shares of ABMD which is valued at $801,016. ABIOMED makes up approx 0.11% of Vident Investment Advisory’s portfolio.Oppenheimerfunds boosted its stake in ABMD in the latest quarter, The investment management firm added 7,544 additional shares and now holds a total of 199,261 shares of ABIOMED which is valued at $24,646,593. ABIOMED makes up approx 0.03% of Oppenheimerfunds’s portfolio. Feltz Wealth Plan added ABMD to its portfolio by purchasing 200 company shares during the most recent quarter which is valued at $24,818.Gilder Gagnon Howe Co boosted its stake in ABMD in the latest quarter, The investment management firm added 67 additional shares and now holds a total of 1,969 shares of ABIOMED which is valued at $233,484. Old Mutual Global Investors (uk) Ltd. sold out all of its stake in ABMD during the most recent quarter. The investment firm sold 145,127 shares of ABMD which is valued $16,871,014.
ABIOMED opened for trading at $119.03 and hit $121.44 on the upside on Monday, eventually ending the session at $120.71, with a gain of 1.64% or 1.95 points. The heightened volatility saw the trading volume jump to 3,03,057 shares. Company has a market cap of $5,195 M.
On the company’s financial health, ABIOMED reported $0.29 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $0.24. The company had revenue of $103.00 million for the quarter, compared to analysts expectations of $97.48 million. The company’s revenue was up 40.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.20 EPS.
Abiomed Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company’s products include Impella 2.5 a percutaneous micro heart pump with an integrated motor and sensors; Impella CP which is primarily used by either interventional cardiologists to support patients in the catheter lab or by surgeons in the heart surgery suite; Impella 5.0 and Impella LD a percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP a percutaneous catheter-based axial flow pump that is designed to allow greater than four liters of flow per minute; AB5000 a circulatory support system for the temporary support of acute heart failure patients in profound shock and Symphony a minimally invasive implantable cardiac assist device.